GSK Ebola vaccine fast-tracked into U.S., UK and African trials

LONDON Thu Aug 28, 2014 6:01am EDT

Related Topics

Photo

Ebola epidemic

Quarantines and isolation units imposed to stop the spread of the worst Ebola outbreak in history.  Slideshow 

LONDON (Reuters) - An experimental Ebola vaccine from GlaxoSmithKline is being fast-tracked into human studies and the company plans to build up a stockpile of up to 10,000 doses for emergency deployment, if results are good.

Britain's biggest drugmaker said on Thursday the research was being accelerated with funding from an international consortium, reflecting mounting concern over the worst-ever outbreak of the disease in West Africa that has killed more than 1,500 people.

The candidate vaccine, which is being co-developed with the U.S. National Institutes of Health (NIH), is expected to be given to healthy volunteers in Britain and the United States from around mid-September, with the program then being extended to volunteers in Gambia and Mali.

(Reporting by Ben Hirschler, Editing by Paul Sandle)

FILED UNDER:
We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/
Comments (1)
Of all the vaccine talk lately, I would vote for the vaccine that’s was created in Winnipeg Canada, as they have been working on it for some years and have very encouraging results, although in primates of course, very promising just the same.

Aug 28, 2014 9:28am EDT  --  Report as abuse
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.